Pfizer (NYSE:PFE) Releases FY 2025 Earnings Guidance

Pfizer (NYSE:PFE) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 3.000-3.150 for the period, compared to the consensus estimate of 3.040. The company issued revenue guidance of $61.0 billion-$64.0 billion, compared to the consensus revenue estimate of $63.0 billion.

Wall Street Analyst Weigh In

A number of brokerages recently commented on PFE. Bank of America boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Morgan Stanley decreased their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average price target of $28.24.

Pfizer Price Performance

Shares of Pfizer stock opened at $24.69 on Tuesday. The firm has a fifty day simple moving average of $24.76 and a 200-day simple moving average of $24.31. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer has a 1-year low of $20.92 and a 1-year high of $28.14. The stock has a market capitalization of $140.40 billion, a price-to-earnings ratio of 13.14, a PEG ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same period in the previous year, the company earned $0.60 earnings per share. Pfizer’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, sell-side analysts expect that Pfizer will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Institutional Investors Weigh In On Pfizer

Hedge funds have recently made changes to their positions in the company. Darwin Wealth Management LLC acquired a new stake in shares of Pfizer during the 2nd quarter worth about $32,000. WFA of San Diego LLC acquired a new stake in shares of Pfizer during the 2nd quarter worth about $40,000. WealthCollab LLC increased its position in shares of Pfizer by 12.5% during the 2nd quarter. WealthCollab LLC now owns 3,985 shares of the biopharmaceutical company’s stock worth $97,000 after purchasing an additional 442 shares in the last quarter. Binnacle Investments Inc increased its position in shares of Pfizer by 65.1% during the 2nd quarter. Binnacle Investments Inc now owns 5,752 shares of the biopharmaceutical company’s stock worth $139,000 after purchasing an additional 2,267 shares in the last quarter. Finally, State of Wyoming increased its position in shares of Pfizer by 77.8% during the 2nd quarter. State of Wyoming now owns 7,427 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 3,251 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.